ANI Pharmaceuticals ANIP ILUVIEN and YUTIQ — Net Revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's iluvien and yutiq — net revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's ILUVIEN and YUTIQ — net revenues?
- ANI Pharmaceuticals (ANIP) reported ILUVIEN and YUTIQ — net revenues of $19.26M in Q1 2026.
- How has ANI Pharmaceuticals's ILUVIEN and YUTIQ — net revenues changed year-over-year?
- ANI Pharmaceuticals's ILUVIEN and YUTIQ — net revenues increased by 19.5% year-over-year, from $16.11M to $19.26M.
- What does ILUVIEN and YUTIQ — net revenues mean?
- This metric represents the total net sales generated from the ILUVIEN and YUTIQ product portfolio after accounting for returns, rebates, and other sales deductions. It serves as a key indicator of the commercial performance and market adoption of these specific ophthalmology assets within the company's specialty pharmaceutical segment. Tracking this revenue stream helps investors evaluate the growth trajectory and contribution of acquired specialty products to the overall corporate top line.